Andrew Dietz MD, MSCR

Dr. Andrew Dietz brings to Ensoma extensive expertise in clinical development, regulatory affairs, and research, with a particular focus on gene and cell therapy and RNA editing technologies. Before joining Ensoma, he led these functions for Shape Therapeutics, where he was instrumental in advancing the company’s preclinical pipeline, which includes innovations in RNA editing, next-generation AAVs, and gene therapy manufacturing.

Drew earned his medical degree from the University of Minnesota, followed by a pediatric residency at Seattle Children’s Hospital and a fellowship in hematology, oncology, and stem cell transplantation at the University of Minnesota. He spent six years in clinical and academic research, where he oversaw pediatric stem cell transplants, designed clinical trial protocols, and served as an investigator in early CAR T-cell trials for pediatric leukemia.

Transitioning to the biotech industry, Drew joined bluebird bio, where he played a critical role in the late-stage clinical trials that led to the regulatory approval of ex vivo lentiviral vector gene therapies in both the U.S. and EU. Drew has also contributed to the development of regulatory strategies and serves as a member of the ARM Gene Therapy Advisory Group and the ASGCT Diversity, Equity, and Inclusion Committee.